Treatment patterns and survival outcomes for small-cell lung cancer patients - a Swedish single center cohort study

被引:18
作者
Tendler, Salomon [1 ,2 ]
Zhan, Yiqiang [3 ]
Pettersson, Andreas [4 ]
Lewensohn, Rolf [1 ,2 ]
Viktorsson, Kristina [1 ,2 ]
Fang, Fang [3 ]
De Petris, Luigi [1 ,2 ]
机构
[1] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden
[2] Karolinska Univ Hosp, Theme Canc Patient Area Head & Neck Lung & Skin C, Stockholm, Sweden
[3] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
[4] Karolinska Inst, Clin Epidemiol Unit, Dept Med Solna, Stockholm, Sweden
关键词
PROPHYLACTIC CRANIAL IRRADIATION; 2ND-LINE CHEMOTHERAPY; OPEN-LABEL; PHASE-III; TOPOTECAN; DISEASE; RECHALLENGE; 2ND;
D O I
10.1080/0284186X.2019.1711165
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: This real-world study on small-cell lung cancer (SCLC) patients aimed to investigate treatment patterns, outcome of re-challenge with platinum doublet chemotherapy (PDCT), and associations between clinical characteristics and survival outcomes. Material and methods: This retrospective single center cohort study was based on patients diagnosed with SCLC between 2008 and 2016 at the Karolinska University Hospital, Stockholm, Sweden. Patients were divided into two subgroups; limited disease (LD), receiving concomitant chemo- and radiotherapy and extensive disease (ED), receiving palliative PDCT. The progression-free survival (PFS) was defined as the interval between the start of CT and the earliest date of documented progression. 'Refractory relapse' (Rr) and 'Sensitive relapse' (Sr) were defined as relapse occurring < or >= 180 days after start of PDCT, respectively. The results for treatment patterns were reported as numbers and percentages of patients, and descriptive analyses including medians and 95% confidence intervals (CIs). The Cox proportional hazards regression model was applied to assess the relationship between clinical characteristics and overall survival (OS). Results: The study included 544 patients; 408 with ED and 136 patients had LD. The median PFS and OS for ED patients were 5.1 and 7.0, respectively. In the ED subgroup, Sr occurred in 169 patients (41%), with a longer median OS when compared to Rr patients (10.8 vs. 3.6 months). Patients with LD had a median PFS and OS of 12 and 24 months, respectively. Some LD patients did not show a sign of relapse (22%). The majority of LD patients who relapsed had Sr (66%), with a longer median OS when compared to patients with Rr (20.9 vs. 7.8 mo). Conclusions: The survival outcomes for ED and LD SCLC patients correspond to historical data. Patients with Sr after 1st line therapy might benefit from re-challenge with PDCT in the 2nd line setting.
引用
收藏
页码:388 / 394
页数:7
相关论文
共 31 条
[1]   Serum lactate dehydrogenase predicts survival in small-cell lung cancer patients with brain metastases that were treated with whole-brain radiotherapy [J].
Anami, Shimpei ;
Doi, Hiroshi ;
Nakamatsu, Kiyoshi ;
Uehara, Takuya ;
Wada, Yutaro ;
Fukuda, Kohei ;
Inada, Masahiro ;
Ishikawa, Kazuki ;
Kanamori, Shuichi ;
Nishimura, Yasumasa .
JOURNAL OF RADIATION RESEARCH, 2019, 60 (02) :257-263
[2]   Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission [J].
Aupérin, A ;
Arriagada, R ;
Pignon, JP ;
Le Péchoux, C ;
Gregor, A ;
Stephens, RJ ;
Kristjansen, PEG ;
Johnson, BE ;
Ueoka, H ;
Wagner, H ;
Aisner, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (07) :476-484
[3]   Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy [J].
Bernhardt, Denise ;
Aufderstrasse, Sophie ;
Koenig, Laila ;
Adeberg, Sebastian ;
Bozorgmehr, Farastuk ;
Christopoulos, Petros ;
El Shafie, Rami A. ;
Hoerner-Rieber, Juliane ;
Kappes, Jutta ;
Thomas, Michael ;
Herth, Felix ;
Steins, Martin ;
Debus, Juergen ;
Rieken, Stefan .
CANCER MANAGEMENT AND RESEARCH, 2018, 10 :6563-6569
[4]   Real-world treatment patterns and outcomes of patients with small cell lung cancer progressing after 2 lines of therapy [J].
Coutinho, Anna D. ;
Shah, Manan ;
Lunacsek, Orsolya E. ;
Eaddy, Michael ;
Willey, Joanne P. .
LUNG CANCER, 2019, 127 :53-58
[5]   Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer [J].
Eckardt, John R. ;
von Pawel, Joachim ;
Pujol, Jean-Louis ;
Papai, Zsolt ;
Quoix, Elisabeth ;
Ardizzoni, Andrea ;
Poulin, Ruth ;
Preston, Alaknanda J. ;
Dane, Graham ;
Ross, Graham .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) :2086-2092
[6]   Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial [J].
Faivre-Finn, Corinne ;
Snee, Michael ;
Ashcroft, Linda ;
Appel, Wiebke ;
Barlesi, Fabrice ;
Bhatnagar, Adityanarayan ;
Bezjak, Andrea ;
Cardenal, Felipe ;
Fournel, Pierre ;
Harden, Susan ;
Le Pechoux, Cecile ;
McMenemin, Rhona ;
Mohammed, Nazia ;
O'Brien, Mary ;
Pantarotto, Jason ;
Surmont, Veerle ;
Van Meerbeeck, Jan P. ;
Woll, Penella J. ;
Lorigan, Paul ;
Blackhall, Fiona .
LANCET ONCOLOGY, 2017, 18 (08) :1116-1125
[7]   Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: A multi-institutional retrospective analysis [J].
Garassino, Marina Chiara ;
Torri, Valter ;
Michetti, Giovanni ;
Lo Dico, Monica ;
La Verde, Nicla ;
Aglione, Stefania ;
Mancuso, Andrea ;
Gallerani, Elisa ;
Galetta, Domenico ;
Martelli, Olga ;
Collova, Elena ;
Fatigoni, Sonia ;
Ghidini, Antonio ;
Saggia, Chiara ;
Bareggi, Claudia ;
Rossi, Antonio ;
Farina, Gabriella ;
Thatcher, Nicholas ;
Blackhall, Fiona ;
Lorigan, Paul ;
Califano, Raffaele .
LUNG CANCER, 2011, 72 (03) :378-383
[8]  
Gaspar Laurie E, 2005, Clin Lung Cancer, V6, P355, DOI 10.3816/CLC.2005.n.015
[9]   Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis [J].
Genestreti, Giovenzio ;
Tiseo, Marcello ;
Kenmotsu, Hirotsugu ;
Kazushige, Wakuda ;
Di Battista, Monica ;
Cavallo, Giovanna ;
Carloni, Federica ;
Bongiovanni, Alberto ;
Burgio, Marco Angelo ;
Casanova, Claudia ;
Metro, Giulio ;
Scarpi, Emanuela ;
Korkmaz, Taner ;
Selcuk, Seber ;
Roopa, Kurup ;
Califano, Raffaele .
CLINICAL LUNG CANCER, 2015, 16 (06) :E223-E228
[10]   First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer [J].
Horn, L. ;
Mansfield, A. S. ;
Szczesna, A. ;
Havel, L. ;
Krzakowski, M. ;
Hochmair, M. J. ;
Huemer, F. ;
Losonczy, G. ;
Johnson, M. L. ;
Nishio, M. ;
Reck, M. ;
Mok, T. ;
Lam, S. ;
Shames, D. S. ;
Liu, J. ;
Ding, B. ;
Lopez-Chavez, A. ;
Kabbinavar, F. ;
Lin, W. ;
Sandler, A. ;
Liu, S. V. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (23) :2220-2229